Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
2023年9月7日 - 8:00PM
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a
commercial-stage biotechnology company focused on the discovery,
development and commercialization of genetic medicines to treat
diseases with high unmet medical needs, announced today that the
Company will participate in the Morgan Stanley 21st Annual
Global Healthcare Conference in New York.
Krish Krishnan, Chairman and Chief Executive Officer, will
participate in a fireside chat during the conference and host
investor meetings on September 12.
A webcast of the presentation will be
available here beginning at 4:55 pm
ET on Tuesday, September 12 and will be posted on
the Investor section of the Company’s website.
About Krystal Biotech, Inc.Krystal Biotech,
Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company
focused on the discovery, development and commercialization of
genetic medicines to treat diseases with high unmet medical needs.
VYJUVEK™ is the Company’s first commercial product, the
first-ever redosable gene therapy, and the only medicine approved
by the FDA for the treatment of dystrophic epidermolysis bullosa.
The Company is rapidly advancing a robust preclinical and clinical
pipeline of investigational genetic medicines in respiratory,
oncology, dermatology, ophthalmology, and aesthetics. Krystal
Biotech is headquartered in Pittsburgh, Pennsylvania. For more
information, please visit http://www.krystalbio.com, and follow
@KrystalBiotech on LinkedIn and Twitter.
CONTACTInvestors and
Media:
Meg Dodge
Krystal Biotech
mdodge@krystalbio.com
Krystal Biotech (NASDAQ:KRYS)
過去 株価チャート
から 4 2024 まで 5 2024
Krystal Biotech (NASDAQ:KRYS)
過去 株価チャート
から 5 2023 まで 5 2024